SCHEMBL216173

SCHEMBL216173

Nc1nn(-c2nccs2)c2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.42
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
GAA P10253 1/20 0.42
G6PD P11413 1/20 0.42
PKM P14618 1/20 0.42
MPI P34949 1/20 0.42
EP300 Q09472 1/20 0.42
KAT2A Q92830 1/20 0.42
KAT2B Q92831 1/20 0.42
SCN9A Q15858 1/20 0.40
TTK P33981 4/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15052361 0.79 PDPK1 (0.41) CYP17A1CYP1A2ALDH1A1KDM4EMAPT
SCHEMBL212821 0.74 HSD17B10 (0.48) CYP17A1CYP1A2ALDH1A1KDM4EMAPT
SCHEMBL2661391 0.74 SCD (0.43) CYP17A1CYP1A2ALDH1A1TDP1SCN9A
SCHEMBL4870334 0.73 KDM4E (0.49) CYP17A1CYP1A2ALDH1A1KDM4EMAPT
SCHEMBL18131343 0.72 RAB9A (0.47) CYP17A1CYP1A2MAPTGAASCN9A
SCHEMBL10831975 0.71 MAPT (0.47) CYP1A2ALDH1A1KDM4EMAPTSCN9A
SCHEMBL25222249 0.70 KHK (0.40) CYP17A1CYP1A2MAPTSCN9ATTK
SCHEMBL25262862 0.69 HTR3A (0.43) KDM4EMAPTSCN9ATTKNPSR1
SCHEMBL25229098 0.69 CYP17A1 (0.45) CYP17A1CYP1A2ALDH1A1SCN9ATTK
SCHEMBL8414958 0.68 RAB9A (0.54) CYP17A1CYP1A2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 EP disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK CYP17A1 3094/4885CYP1A2 1318/4885ALDH1A1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.